Envestnet Asset Management Inc. Has $188.66 Million Stock Holdings in Novartis AG (NYSE:NVS)

Envestnet Asset Management Inc. trimmed its stake in shares of Novartis AG (NYSE:NVS) by 0.8% during the fourth quarter, Holdings Channel reports. The firm owned 1,938,731 shares of the company’s stock after selling 14,966 shares during the period. Envestnet Asset Management Inc.’s holdings in Novartis were worth $188,658,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. Bryn Mawr Capital Management LLC grew its position in Novartis by 0.8% in the fourth quarter. Bryn Mawr Capital Management LLC now owns 12,884 shares of the company’s stock valued at $1,254,000 after acquiring an additional 100 shares during the period. Rothschild Investment LLC boosted its stake in shares of Novartis by 0.6% in the 4th quarter. Rothschild Investment LLC now owns 16,682 shares of the company’s stock valued at $1,623,000 after purchasing an additional 101 shares in the last quarter. Meridian Wealth Management LLC grew its holdings in shares of Novartis by 2.6% in the 4th quarter. Meridian Wealth Management LLC now owns 4,161 shares of the company’s stock worth $405,000 after purchasing an additional 106 shares during the last quarter. Angeles Wealth Management LLC increased its position in shares of Novartis by 3.5% during the 4th quarter. Angeles Wealth Management LLC now owns 3,249 shares of the company’s stock worth $316,000 after purchasing an additional 110 shares in the last quarter. Finally, Heritage Family Offices LLP lifted its holdings in Novartis by 1.9% during the 4th quarter. Heritage Family Offices LLP now owns 6,107 shares of the company’s stock valued at $594,000 after purchasing an additional 112 shares during the last quarter. 13.12% of the stock is currently owned by institutional investors.

Novartis Price Performance

Novartis stock opened at $105.79 on Monday. The stock has a market cap of $216.24 billion, a price-to-earnings ratio of 17.99, a P/E/G ratio of 1.70 and a beta of 0.56. Novartis AG has a 12-month low of $92.35 and a 12-month high of $120.92. The company has a quick ratio of 0.84, a current ratio of 1.04 and a debt-to-equity ratio of 0.48. The business’s 50-day simple moving average is $109.02 and its 200 day simple moving average is $106.92.

Novartis (NYSE:NVS) last issued its earnings results on Friday, January 31st. The company reported $1.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.80 by $0.18. Novartis had a net margin of 23.56% and a return on equity of 37.24%. As a group, research analysts anticipate that Novartis AG will post 8.45 earnings per share for the current year.

Novartis Announces Dividend

The firm also recently announced a dividend, which was paid on Wednesday, March 12th. Shareholders of record on Wednesday, March 12th were given a dividend of $3.8695 per share. The ex-dividend date of this dividend was Wednesday, March 12th. Novartis’s payout ratio is 42.69%.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. StockNews.com raised shares of Novartis from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 8th. Morgan Stanley initiated coverage on Novartis in a report on Wednesday, February 12th. They set an “underweight” rating for the company. UBS Group reissued a “neutral” rating on shares of Novartis in a research note on Thursday, February 13th. Barclays restated an “underweight” rating on shares of Novartis in a research note on Monday, February 3rd. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Novartis from a “hold” rating to a “buy” rating in a research report on Tuesday, February 4th. Three analysts have rated the stock with a sell rating, six have assigned a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $123.38.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.